Nicole Forgione

Nicole Forgione manages key relationships with industry and proposals for government funding at CCRM. A strong grounding in academic research helps her to understand the science behind new technologies in cell and gene therapy that CCRM is working to commercialize. Dr. Forgione obtained her Master’s degree from the University of Toronto (U of T) in the Department of Zoology and continued graduate studies at U of T in the Department of Cell and Systems Biology, where she completed a PhD in developmental neurobiology under the supervision of Dr. Vince Tropepe. Dr. Forgione went on to pursue studies in translational science with Dr. Michael Fehlings at the Krembil Research Institute in Toronto. Her post-doctoral work focused on animal models of spinal cord injury and cell based therapy for spinal cord regeneration. Nicole’s interest in science communication started early, with an undergraduate double major in English and Biology from Wilfrid Laurier University. Now she focuses her writing on anything and everything related to regenerative medicine technology. Follow Nicole on Twitter @DrNForgione.

Posts by: Nicole

RMConnectTO: Building networks to advance regenerative medicine

Author: Nicole Forgione, 10/12/17

Most people will tell you they hate networking. No matter how much we might dread awkward chit chat, networking and relationship building are key contributors to success, regardless of industry or job title. Because commercializing regenerative medicine (RM) technologies depends on collaboration across diverse sectors, relationship building is critical. With this in mind, RMConnectTO was…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Inaugural Medicine by Design Symposium – Engineering progress in regenerative medicine

Author: Nicole Forgione, 12/21/16

On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114…Read more

Making connections – advancing regenerative medicine through partnerships

Author: Nicole Forgione, 11/08/16

A key driver for advancements in regenerative medicine is partnerships. In recognition of this, every year CCRM hosts a networking reception that brings together our partners for an evening of discussion and knowledge sharing. This year’s industry networking reception was focused on the theme of increasing partnerships between industry and academia. I had the privilege…Read more

Controversial “three-person embryos” should be approved for clinical trials in the U.S.

Author: Nicole Forgione, 03/31/16

Stem cell technology and reproductive medicine have always been tightly linked. After all, the early embryo is essentially a ball of stem cells. For this post, I will delve into a hot topic in reproductive medicine—three-person embryos. Similar to what we have seen with many cell therapies, this technology illustrates the potential of discoveries in…Read more

Japan is innovating to improve access to regenerative medicine technologies

Author: Nicole Forgione, 02/29/16

Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a seminar in Toronto. This meeting brought together Canadian and Japanese experts from government,…Read more

Series: Spotlight on Cell Therapy

Author: Nicole Forgione, 02/17/16

Cell therapy is not a new idea. Bone marrow transplantation—the first ever cell therapy—has been around since the 1950s. Over half a century of research has brought important advancements, yet this technology has struggled to make it to prime time. Understandably, there is scepticism about whether cell therapy will live up to the hype. Recently,…Read more

Canada: Science is in our blood

Author: Nicole Forgione, 12/01/15

November was a big month for science in Canada. Our new prime minister, Justin Trudeau, sent a clear message that science will be a priority for his administration by naming Dr. Kirsty Duncan Minister of Science, and Navdeep Bains Minister of Innovation, Science and Economic Development. Following closely on these exciting political developments, a landmark…Read more

Skin stem cells provide hope for treating burn victims

Author: Nicole Forgione, 11/03/15

At one point or another we’ve all experienced a bad haircut. We get over such minor annoyances secure in the knowledge that “it will grow back.” The ability of our hair to grow back is based on the amazing capacity of the hair follicle to undergo continuous cycles of growth and regrowth throughout our lifetime….Read more

CRISPR/Cas9 gene editing: Is truth becoming stranger than fiction?

Author: Nicole Forgione, 10/15/15

Last week, a Nature News article reported that the Harvard geneticist George Church had modified over 60 genes in pig embryos using CRISPR/Cas9 gene editing. I’m sure you’re expecting my scientific perspective on the significance of this news in the context of the excitement and controversy over CRISPR-Cas9 gene editing—and I will discuss that here….Read more